Trial Profile

A phase 3 trial assessing mavoglurant for treatment of cocaine-use disorder

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 May 2024 According to a STALICLA media release, company the First Patient First Visit (FPFV) for the drug-drug interaction (DDI) study of STP7 (Mavoglurant) licensed to STALICLA by Novartis. The DDI study is the last regulatory requirement in a comprehensive Phase 2 program and completion is expected to trigger initiation of a Phase 3 study in the U.S. in 2025.
02 May 2024 Status changed from planning to recruiting, according to a STALICLA media release.
16 Jan 2024 According to STALICLA media release, the company planned to launch launch this study slated for 2025, fully supported by the NIH /National Institute on Drug Abuse.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com